Ultra-concentrated rapid acting insulin aspart (Arecor)

N/A

Report date: 2024/09/14 09:57:23

Base Information

Drug NameUltra-concentrated rapid acting insulin aspart (Arecor)
Drug Alias NameUltra-concentrated insulin (Arecor)AT278AT-278
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustria
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesArecor Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSequel Med Tech LLCArecor Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A